81 / 89
81
34.
Lahuerta JJ, Martinez-Lopez J, Grande C, Bladé J, de la
Serna J, Alegre A, et al. Conditioning regimens in
autologous stem cell transplantation for multiple
myeloma: a comparative study of efficacy and toxicity
from the Spanish Registry for Transplantation in Multiple
Myeloma. Br J Haematol 2000;109:138-47.
35.
Lahuerta JJ, Grande C, Blade J, Martínez-López J, de la
Serna J, Alegre A, et al. Myeloablative treatments for
multiple myeloma: update of a comparative study of
different regimens used in patients from the Spanish
registry for transplantation in multiple myeloma. Leuk
Lymphoma 2002;43:67-74.
36.
Ria R, Falzetti F, Ballanti S, Minelli O, Di Ianni M,
Cimminiello M, et al. Melphalan versus melphalan plus
busulphan in conditioning to autologous stem cell
transplantation for low-risk multiple myeloma. Hematol J
2004;5:118-22.
37.
Fermand JP, Katsahian S, Divine M, Leblond V, Dreyfus
F, Macro M, et al. High-dose therapy and autologous
blood
stem-cell
transplantation
compared
with
conventional treatment in myeloma patients aged 55 to 65
years: long-term results of a randomized control trial
from the Group Myelome-Autogreffe. J Clin Oncol
2005;23:9227-33.
38.
Benson DM Jr, Elder PJ, Lin TS, Blum W, Penza S, Avalos
B, et al. High-dose melphalan versus busulfan,
cyclophosphamide, and etoposide as preparative
regimens for autologous stem cell transplantation in
patients with multiple myeloma. Leuk Res 2007;31:1069-
75.
39.
Lahuerta JJ, Mateos MV, Martínez-López J, Grande C, de
la Rubia J, Rosiñol L, et al. Busulfan 12 mg/kg plus
melphalan 140 mg/m
2
versus melphalan 200 mg/m
2
as
conditioning regimens for autologous transplantation in